• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非典型角化细胞滤泡延伸预示着光化性角化病对外用咪喹莫特治疗的耐药性:一项单中心回顾性分析。

Follicular extension of atypical keratinocytes predicts the resistance of actinic keratosis to topical imiquimod treatment: A single-center retrospective analysis.

机构信息

Department of Dermatology, Hiratsuka City Hospital, Hiratsuka, Japan.

Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.

出版信息

J Dermatol. 2021 Aug;48(8):1262-1267. doi: 10.1111/1346-8138.15914. Epub 2021 Apr 25.

DOI:10.1111/1346-8138.15914
PMID:33896047
Abstract

Topical imiquimod therapy has been widely used for actinic keratosis (AK). However, some cases are refractory to treatment. Therefore, an indicator that can predict its efficacy is desired. Herein, we retrospectively analyzed 52 AK lesions treated with imiquimod to investigate the characteristics of refractory lesions. Imiquimod was applied in a cycle of three times weekly for 4 weeks, followed by a 4-week break. This treatment cycle was repeated up to three times and treatment responses were evaluated. As a result, a complete response (CR) was observed in 78.8% (41/52) of lesions. Next, treatment response of lesions was correlated with clinicopathological characteristics including clinical morphology and thickness, pathological morphology and thickness, and presence of follicular extension (FE). Of these, lesions with FE were significantly less responsive to imiquimod treatment; while 92.6% of AK lesions without FE achieved a CR, only 64.0% of AK lesions with FE achieved a CR (p = 0.029). Logistic regression analysis revealed that FE was the sole significant predictor of its efficacy (p = 0.019). These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.

摘要

咪喹莫特局部治疗已广泛用于光化性角化病(AK)。然而,有些病例对治疗有抗性。因此,需要一种可以预测其疗效的指标。在此,我们回顾性分析了 52 例接受咪喹莫特治疗的 AK 病变,以探讨难治性病变的特征。咪喹莫特每周应用 3 次,持续 4 周,然后休息 4 周。该治疗周期最多重复 3 次,并评估治疗反应。结果,78.8%(41/52)的病变完全缓解(CR)。接下来,将病变的治疗反应与临床病理特征相关联,包括临床形态和厚度、病理形态和厚度以及滤泡延伸(FE)的存在。其中,有 FE 的病变对咪喹莫特治疗的反应明显较差;而无 FE 的 AK 病变 92.6%达到 CR,仅有 FE 的 AK 病变 64.0%达到 CR(p=0.029)。逻辑回归分析显示,FE 是其疗效的唯一显著预测因素(p=0.019)。这些结果表明,FE 的初步组织学评估可能有助于预测咪喹莫特治疗 AK 的疗效。

相似文献

1
Follicular extension of atypical keratinocytes predicts the resistance of actinic keratosis to topical imiquimod treatment: A single-center retrospective analysis.非典型角化细胞滤泡延伸预示着光化性角化病对外用咪喹莫特治疗的耐药性:一项单中心回顾性分析。
J Dermatol. 2021 Aug;48(8):1262-1267. doi: 10.1111/1346-8138.15914. Epub 2021 Apr 25.
2
Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.光化性角化病的临床和组织病理学分类与局部咪喹莫特治疗效果的相关性。
J Dermatol. 2018 Apr;45(4):496-500. doi: 10.1111/1346-8138.14192. Epub 2017 Dec 19.
3
Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.一项开放标签研究,旨在评估5%咪喹莫特乳膏每周三次、每日一次循环给药治疗头部光化性角化病的安全性和有效性。
J Cutan Med Surg. 2008 May-Jun;12(3):97-101. doi: 10.2310/7750.2008.07045.
4
Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.比较研究光动力疗法、咪喹莫特免疫疗法及其联合疗法对 40 例日本患者光化性角化病皮损的疗效。
J Dermatol. 2013 Dec;40(12):962-7. doi: 10.1111/1346-8138.12310. Epub 2013 Oct 22.
5
Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.咪喹莫特治疗中,交叉偏振光和荧光诊断对亚临床和临床光化性角化病的检测效果。
Exp Dermatol. 2010 Jul 1;19(7):641-7. doi: 10.1111/j.1600-0625.2009.01047.x. Epub 2010 Feb 25.
6
Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.长期使用咪喹莫特 3.75%持续清除 Lmax 病变,一种新的光化性角化病的定向治疗方法。
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1840-2. doi: 10.1111/jdv.12697. Epub 2014 Aug 29.
7
Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.使用5%咪喹莫特乳膏治疗光化性角化病后的长期临床结果。
Dermatol Surg. 2005 Jun;31(6):659-64. doi: 10.1111/j.1524-4725.2005.31608.
8
Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.用咪喹莫特有效治疗的光化性角化病皮损中真皮内肥大细胞数量增加。
J Dermatol. 2017 Aug;44(8):944-949. doi: 10.1111/1346-8138.13821. Epub 2017 Mar 24.
9
Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.根据光化性角化病皮损数量,来自Lmax的3.75%咪喹莫特的疗效。
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2470-3. doi: 10.1111/jdv.12782. Epub 2014 Oct 28.
10
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.咪喹莫特2.5%和3.75%用于治疗光化性角化病:两项3期、多中心、随机、双盲、安慰剂对照研究。
J Drugs Dermatol. 2014 Feb;13(2):166-9.

引用本文的文献

1
Dynamic optical coherence tomography unveils subclinical, vascular differences across actinic keratosis grades I-III.动态光学相干断层扫描揭示了 I-III 级光化性角化病各等级的亚临床血管差异。
Exp Dermatol. 2024 Aug;33(8):e15153. doi: 10.1111/exd.15153.